miRNA expression assay

The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.

The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.

The all-cash deal gives Abcam access to Firefly's multiplex assay biomarker-detection platform.

Researchers from the University Health Network in Toronto, the Mayo Clinic, Ohio State University, and University of Miami School of Medicine are among the early-access customers who have been using the product ahead of its commercial launch this week.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.